cgp 42112a has been researched along with phenylalanine in 1 studies
| Studies (cgp 42112a) | Trials (cgp 42112a) | Recent Studies (post-2010) (cgp 42112a) | Studies (phenylalanine) | Trials (phenylalanine) | Recent Studies (post-2010) (phenylalanine) |
|---|---|---|---|---|---|
| 233 | 0 | 35 | 23,695 | 721 | 4,367 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akira, T; Egi, Y; Maruyama, T; Matsumura, Y; Ohkita, M; Sasaoka, T; Takaoka, M; Tawa, M; Yamamoto, A | 1 |
1 other study(ies) available for cgp 42112a and phenylalanine
| Article | Year |
|---|---|
Angiotensin II type 2 receptor-mediated inhibition of norepinephrine release in isolated rat hearts.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Bradykinin; Heart; Imidazoles; In Vitro Techniques; Losartan; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Norepinephrine; Oligopeptides; Phenylalanine; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sympathetic Nervous System; Tranexamic Acid; Vasoconstrictor Agents | 2008 |